Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab Combined with Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer
NCT07003815Phase 2Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of envafolimab in biliary tract cancer (BTC), sponsored by Tongji Hospital. Primary endpoint: Objective Response Rate at 24 weeks. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
envafolimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07003815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07003815.